US biotech Sarepta Therapeutics (Nasdaq: SRPT) unveiled mixed results late Monday for its gene therapy Elevidys (delandistrogene moxeparvovec-rokl) in patients with Duchenne muscular dystrophy between the ages of four through seven years. The stock was halted in late trading.
In the study, Elevidys-treated patients improved 2.6 points on their North Star Ambulatory Assessment (NSAA) total score 52 weeks after treatment compared to 1.9 points in placebo-treated patients.
However, the trial missed the primary North Star Ambulatory Assessment/NSAA endpoint, with a treatment difference of 0.65-points (p=0.2441).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze